Zobrazeno 1 - 10 of 36 pro vyhledávání: '"Nathalie, Aucoin"'
1
Akademický článek
Plasma arginine as a predictive biomarker for outcomes with immune checkpoint inhibition in metastatic colorectal cancer: a correlative analysis of the CCTG CO.26 trial
Autor: Christopher O’Callaghan, Scott Berry, Petr Kavan, Jonathan M Loree, Felix Couture, Dongsheng Tu, Sheryl Koski, Lucy X Ma, Emma Titmuss, Derek J Jonker, Hagen F Kennecke, Chaudhary E Ahmad, John R Goffin, Mohammed Harb, Bruce Colwell, Setareh Samimi, Benoit Samson, Tahir Abbas, Nathalie Aucoin, Francine Aubin, Eric X Chen
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 12, Iss 12 (2024)
Background Nutritional stress is a mechanism that allows tumor cells to evade the immune system. Arginine (ARG), an amino acid involved in immunomodulation, aids in regulating T-lymphocyte cell activity and the antitumor response. ARG deficiency in t
Externí odkaz: https://doaj.org/article/049a1ab63a0c4bb59840eb50e1b906d5
Zobrazit plný text záznamu
2
Akademický článek
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma
Autor: Daniel J. Renouf, Jonathan M. Loree, Jennifer J. Knox, James T. Topham, Petr Kavan, Derek Jonker, Stephen Welch, Felix Couture, Frederic Lemay, Mustapha Tehfe, Mohammed Harb, Nathalie Aucoin, Yoo-Joung Ko, Patricia A. Tang, Ravi Ramjeesingh, Brandon M. Meyers, Christina A. Kim, Pan Du, Shidong Jia, David F. Schaeffer, Sharlene Gill, Dongsheng Tu, Chris J O’Callaghan
Publikováno v: Nature Communications, Vol 13, Iss 1, Pp 1-8 (2022)
Metastatic pancreatic ductal adenocarcinoma (mPDAC) has limited therapeutic options and is associated with a poor prognosis. Here the authors report the results of a randomized phase II trial showing that combining checkpoint inhibitors (durvalumab a
Externí odkaz: https://doaj.org/article/ccff0c483c6e49d4b8726cac04df8470
Zobrazit plný text záznamu
5
A retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada
Autor: Melanie Poulin-Costello, Brad Gillesby, Jean A. Maroun, Félix Couture, Hagen F. Kennecke, Scott R. Berry, Nathalie Aucoin, Petr Kavan
Publikováno v: Current Oncology
Volume 26
Issue 6
Pages 4861-754
Background: Selection and sequencing of treatment regimens for individual patients with metastatic colorectal cancer (mcrc) is driven by maintaining reasonable quality of life and extending survival, as well as by access to and cost of therapies. The
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a612534e70f74902482c141a2c8650e
https://pubmed.ncbi.nlm.nih.gov/31896945
Zobrazit plný text záznamu
7
Abstract P4-14-19: ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets)
Autor: Erika Hamilton, Carla I. Falkson, Stephen Welch, Virginia F. Borges, Cristiano Ferrario, Luke Walker, Jorge Chaves, S. L. Moulder, Ravi Murthy, Nathalie Aucoin
Publikováno v: Cancer Research. 76:P4-14
Background: The risk of CNS involvement in patients with HER2+ metastatic breast cancer (MBC) is high. The natural history of HER2+ CNS metastases (mets) is different from other breast cancer subtypes; there is a longer time from metastatic diagnosis
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::eeaed127c3a1c893722fe66386a19b59
https://doi.org/10.1158/1538-7445.sabcs15-p4-14-19
Zobrazit plný text záznamu
8
Abstract P4-14-20: A phase 1b study of ONT 380, an oral HER2-specific inhibitor, combined with ado trastuzumab emtansine (T DM1), in HER2+ metastatic breast cancer (MBC)
Autor: Cristiano Ferrario, Ian E. Krop, Qamar J. Khan, Alison Conlin, Erika Hamilton, P. Bedard, Carla I. Falkson, A Vo, Nathalie Aucoin, Jorge Chaves, Virginia F. Borges, Luke Walker, Stephen Welch
Publikováno v: Cancer Research. 76:P4-14
Background: ONT 380 is a potent HER2 selective tyrosine kinase inhibitor with minimal EGFR-like side effects. Preclinical studies demonstrate synergism with trastuzumab (T) and chemotherapy, as well as activity in models of HER2+ CNS disease. Based o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2a8901123966123a5fe957229436bf6f
https://doi.org/10.1158/1538-7445.sabcs15-p4-14-20
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje